dg-Bcan-Targeting Peptide 7/BTP-7

dg-Bcan-Targeting Peptide 7/BTP-7

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-tkwGhvnk-OH

H-(D)-Thr-(D)-Lys-(D)-Trp-Gly-(D)-His-(D)-Val-(D)-Asn-(D)-Lys-OH

8

95.42%

C₄₄H₆₈N₁₄O₁₁

969.09

Synthetic

Powder

dg-Bcan (a Brevican isoform lacking most glycosylation) is explored as a molecular target for GBM(Glioblastoma multiforme). BTP-7 binds dg-Bcan with high affinity and specificity. BTP-7 is preferentially internalized by dg-Bcan-expressing patient-derived GBM cells. BTP-7 represents a promising lead candidate for further development into novel imaging agents and targeted therapeutics.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• von Spreckelsen N, Fadzen CM, Hartrampf N, Ghotmi Y, Wolfe JM, Dubey S, Yang BY, Kijewski MF, Wang S, Farquhar C, Bergmann S, Zdioruk M, Wasserburg JR, Scott B, Murrell E, Bononi FC, Luyt LG, DiCarli M, Lamfers MLM, Ligon KL, Chiocca EA, Viapiano MS, Pentelute BL, Lawler SE, Cho CF. Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican. Adv Ther (Weinh). 2021 Apr;4(4):2000244. doi: 10.1002/adtp.202000244. Epub 2021 Jan 20. PMID: 33997269; PMCID: PMC8114962.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.